vs
MESA LABORATORIES INC（MLAB）与null（SWIM）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是MESA LABORATORIES INC的1.8倍（$117.3M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -7.3%，领先12.8%），null同比增速更快（5.3% vs 3.6%），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -14.4%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
该企业是一家源自美国的跨国律师事务所，1934年创立于加利福尼亚州洛杉矶，在诉讼业务、公司法务以及监管合规法律领域拥有深厚的行业积累与知名度，是全球颇具影响力的综合性律所之一。
MLAB vs SWIM — 直观对比
营收规模更大
SWIM
是对方的1.8倍
$65.1M
营收增速更快
SWIM
高出1.7%
3.6%
净利率更高
MLAB
高出12.8%
-7.3%
两年增速更快
MLAB
近两年复合增速
-14.4%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $117.3M |
| 净利润 | $3.6M | $-8.5M |
| 毛利率 | 64.2% | 31.7% |
| 营业利润率 | 12.2% | — |
| 净利率 | 5.6% | -7.3% |
| 营收同比 | 3.6% | 5.3% |
| 净利润同比 | 316.6% | -43.1% |
| 每股收益（稀释后） | $0.65 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABSWIM
| Q1 26 | — | $117.3M | ||
| Q4 25 | $65.1M | $100.0M | ||
| Q3 25 | $60.7M | $161.9M | ||
| Q2 25 | $59.5M | $172.6M | ||
| Q1 25 | $62.1M | $111.4M | ||
| Q4 24 | $62.8M | $87.3M | ||
| Q3 24 | $57.8M | $150.5M | ||
| Q2 24 | $58.2M | $160.1M |
净利润MLABSWIM
| Q1 26 | — | $-8.5M | ||
| Q4 25 | $3.6M | $-7.0M | ||
| Q3 25 | $2.5M | $8.1M | ||
| Q2 25 | $4.7M | $16.0M | ||
| Q1 25 | $-7.1M | $-6.0M | ||
| Q4 24 | $-1.7M | $-29.2M | ||
| Q3 24 | $3.4M | $5.9M | ||
| Q2 24 | $3.4M | $13.3M |
毛利率MLABSWIM
| Q1 26 | — | 31.7% | ||
| Q4 25 | 64.2% | 28.0% | ||
| Q3 25 | 61.5% | 35.4% | ||
| Q2 25 | 62.0% | 37.1% | ||
| Q1 25 | 61.8% | 29.5% | ||
| Q4 24 | 63.3% | 24.6% | ||
| Q3 24 | 61.3% | 32.4% | ||
| Q2 24 | 64.0% | 33.1% |
营业利润率MLABSWIM
| Q1 26 | — | — | ||
| Q4 25 | 12.2% | -10.7% | ||
| Q3 25 | 7.8% | 13.3% | ||
| Q2 25 | 5.1% | 14.3% | ||
| Q1 25 | 2.4% | -4.4% | ||
| Q4 24 | 9.2% | -14.9% | ||
| Q3 24 | 6.1% | 8.9% | ||
| Q2 24 | 9.6% | 12.5% |
净利率MLABSWIM
| Q1 26 | — | -7.3% | ||
| Q4 25 | 5.6% | -7.0% | ||
| Q3 25 | 4.1% | 5.0% | ||
| Q2 25 | 8.0% | 9.3% | ||
| Q1 25 | -11.4% | -5.4% | ||
| Q4 24 | -2.7% | -33.4% | ||
| Q3 24 | 5.9% | 3.9% | ||
| Q2 24 | 5.8% | 8.3% |
每股收益（稀释后）MLABSWIM
| Q1 26 | — | $-0.07 | ||
| Q4 25 | $0.65 | $-0.06 | ||
| Q3 25 | $0.45 | $0.07 | ||
| Q2 25 | $0.85 | $0.13 | ||
| Q1 25 | $-1.30 | $-0.05 | ||
| Q4 24 | $-0.31 | $-0.24 | ||
| Q3 24 | $0.63 | $0.05 | ||
| Q2 24 | $0.62 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | — |
| 总债务越低越好 | $68.4M | $3.3M |
| 股东权益账面价值 | $186.7M | $396.7M |
| 总资产 | $434.8M | $856.4M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资MLABSWIM
| Q1 26 | — | — | ||
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | — | ||
| Q2 25 | $21.3M | — | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — |
总债务MLABSWIM
| Q1 26 | — | $3.3M | ||
| Q4 25 | $68.4M | $279.8M | ||
| Q3 25 | $69.4M | $281.1M | ||
| Q2 25 | $70.3M | $281.5M | ||
| Q1 25 | $71.3M | $306.9M | ||
| Q4 24 | $72.2M | $281.5M | ||
| Q3 24 | $73.1M | $282.8M | ||
| Q2 24 | $74.1M | $282.4M |
股东权益MLABSWIM
| Q1 26 | — | $396.7M | ||
| Q4 25 | $186.7M | $405.9M | ||
| Q3 25 | $178.5M | $408.4M | ||
| Q2 25 | $172.5M | $398.4M | ||
| Q1 25 | $159.8M | $381.1M | ||
| Q4 24 | $155.2M | $387.2M | ||
| Q3 24 | $161.5M | $416.6M | ||
| Q2 24 | $150.7M | $408.1M |
总资产MLABSWIM
| Q1 26 | — | $856.4M | ||
| Q4 25 | $434.8M | $823.2M | ||
| Q3 25 | $430.4M | $844.4M | ||
| Q2 25 | $435.7M | $822.1M | ||
| Q1 25 | $433.3M | $824.6M | ||
| Q4 24 | $433.3M | $794.2M | ||
| Q3 24 | $454.1M | $853.4M | ||
| Q2 24 | $440.4M | $830.0M |
负债/权益比MLABSWIM
| Q1 26 | — | 0.01× | ||
| Q4 25 | 0.37× | 0.69× | ||
| Q3 25 | 0.39× | 0.69× | ||
| Q2 25 | 0.41× | 0.71× | ||
| Q1 25 | 0.45× | 0.81× | ||
| Q4 24 | 0.47× | 0.73× | ||
| Q3 24 | 0.45× | 0.68× | ||
| Q2 24 | 0.49× | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 27.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABSWIM
| Q1 26 | — | $-47.7M | ||
| Q4 25 | $18.8M | $23.3M | ||
| Q3 25 | $8.2M | $51.0M | ||
| Q2 25 | $1.9M | $36.0M | ||
| Q1 25 | $12.7M | $-46.9M | ||
| Q4 24 | $18.1M | $6.2M | ||
| Q3 24 | $5.3M | $37.2M | ||
| Q2 24 | $10.7M | $52.4M |
自由现金流MLABSWIM
| Q1 26 | — | — | ||
| Q4 25 | $18.0M | $14.1M | ||
| Q3 25 | $7.1M | $45.2M | ||
| Q2 25 | $884.0K | $29.1M | ||
| Q1 25 | $11.9M | $-50.3M | ||
| Q4 24 | $17.3M | $-98.0K | ||
| Q3 24 | $3.5M | $33.2M | ||
| Q2 24 | $9.9M | $47.9M |
自由现金流率MLABSWIM
| Q1 26 | — | — | ||
| Q4 25 | 27.7% | 14.1% | ||
| Q3 25 | 11.7% | 27.9% | ||
| Q2 25 | 1.5% | 16.8% | ||
| Q1 25 | 19.2% | -45.2% | ||
| Q4 24 | 27.6% | -0.1% | ||
| Q3 24 | 6.0% | 22.1% | ||
| Q2 24 | 16.9% | 29.9% |
资本支出强度MLABSWIM
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 9.2% | ||
| Q3 25 | 1.8% | 3.6% | ||
| Q2 25 | 1.7% | 4.0% | ||
| Q1 25 | 1.2% | 3.1% | ||
| Q4 24 | 1.3% | 7.2% | ||
| Q3 24 | 3.1% | 2.7% | ||
| Q2 24 | 1.5% | 2.8% |
现金转化率MLABSWIM
| Q1 26 | — | — | ||
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | 6.29× | ||
| Q2 25 | 0.40× | 2.25× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | 6.32× | ||
| Q2 24 | 3.17× | 3.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
SWIM
暂无分部数据
